Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  De Marinis, Filippo ^a,b   Gebbia, V ^c,d   De Petris, L ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b FoRO (Oncological Research Foundation)   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Early stage; Molecular markers analysis; Neoadjuvant chemotherapy; Neoadjuvant radiotherapy; NSCLC; Stage IIIA N2

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; K RAS PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; MITOMYCIN; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; VINBLASTINE; VINDESINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 30644468490     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi920     Document Type: Article

References (42)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
2. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: A guide for future studies. J Clin Oncol 1984; 2: 1352-1358.
3. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
4. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Semin Oncol 1997; 24: 429-439.
5. Eberhardt WE, Albain KS, Pass H et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 2003; 42 (Suppl 1): S9-S14.
6. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Ciin Oncol 2000; 18(16): 2981-2989.
7. Strauss GM, Langer MP, Elias AD et al. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: A critical review of the literature and strategies for future research. J Clin Oncol 1992; 10: 829-838.
8. Johnson DH, Piantadosi S. Chemotherapy for resectable stage III non-small-cell lung cancer - can that dog hunt? J Natl Cancer Inst 1994; 86: 650-651.
9. Albain KS. Induction chemotherapy with/without radiation followed by surgery in stage III non-small-cell lung cancer. Oncology (Huntingt) 1997; 11 (Suppl 9): 51-57.
10. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer. mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-1892.
11. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158.
12. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing preooperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.
13. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253.
14. Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7-14.
15. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
16. Nagai K, Tsuchiya R, Mori T et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125: 254-260.
17. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
18. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
19. Van Zandwijk N, Smit EF, Kramer GW et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18: 2658-2664.
20. Betticher DC, Hsu Schmitz SF, Totsch M et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 2003; 21: 1752-1759.
21. O'Brien ME, Splinter T, Smit EF et al. Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). Eur J Cancer 2003; 39: 1416-1422.
22. Santo A, Pedersini R, Pasini F et al. A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: Interim analysis. Lung Cancer 2001; 4 (Suppl 4): S15-S20.
23. Migliorino MR, De Marinis F, Nelli F et al. A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer. Lung Cancer 2002; 35: 319-327.
24. Cappuzzo F, Selvaggi G, Gregorc V et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: An Italian Lung Cancer Project Observational Study. Cancer 2003; 98: 128-134.
25. Frasci G, Panza N, Comella P et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol 1999; 17: 2316-2325.
26. Delbaldo C, Michiels S, Syz N et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. J Amer Med Assoc 2004; 292: 470-484.
27. De Marinis F, Nelli F, Migliorino MR et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: A Phase II multicenter study. Cancer 2003; 98: 1707-1715.
28. Cappuzzo F, De Marinis F, Nelli F et al. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. Lung Cancer 2003; 42: 355-361.
29. Leon L, Cueva-Banuelos JF, Huidobro G et al. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: A multicentre study of galician-lung-cancer-group. Lung Cancer 2003; 40: 215-220.
30. Albain KS, Scott CB, Rusch VR et al. Phase In comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22: (Abstr 2497).
31. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Onco12004; 23: (Abstr 7019).
32. Winton TL, Livingston R, Johnson D et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc Am Soc Clin Oncol 2004; 23: (Abstr 7018).
33. Pisters KM, Ginsberg RJ, Giroux DJ et al. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000; 119: 429-439.
34. Meert AP, Martin B, Verdebout JM et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004; 44: 295-301.
35. Kandioler-Eckersberger D, Kappel S, Mittlbock M et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117: 744-750.
36. Rosell R, Felip E, Taron M et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10 (12 Pt 2): 4215s-4219s.
37. ESMO. Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2001; 12: 1049-1050.
38. De Pas T, Pelosi G, de Braud F et al. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 2004; 22: 4966-4970.
39. Johnson EA, Klimstra DS, Herndon JE 2nd et al. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest 2002; 20: 686-692.
40. Junker K, Wiethege T, Muller KM, Thomas M. p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy. J Cancer Res Clin Oncol 2000; 126: 238.
41. Korobowicz E, Zdunek M. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy. Pol J Pathol 2000; 51: 71-76.
42. Rusch V, Klimstra D, Venkatraman E et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-5042.